Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR …

Background Five major first-and second-generation epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …

Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …

Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Objective To determine the efficacy of first-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non …

The study was to compare the effectiveness of different epidermal growth factor receptor—
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …

An ideal target-based agent for the treatment of cancer patients should fulfil a number of
requirements, including the availability of biomarkers to select the target population …

Materials And Methods We performed a meta-analysis of the main randomized clinical trials
evaluating the currently approved EGFR-TKIs in first-line of treatment of EGFR-positive …

Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …